PUBLIC COMPANY
saveBARR
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitroAstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in…biospace · 16d ago
- AstraZeneca heralds new R&D facility in that ‘other’ CambridgeAstraZeneca prides itself on investing roughly a quarter of its annual revenue into research and development. On Monday, the company inaugurated a 570,000-square-foot building in Cambridge, MA, tha…endpoints · 25d ago
- AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D centerAstraZeneca executives touted the benefits of further establishing themselves in Massachusetts’ biopharma “ecosystem” as the Big Pharma opened a new R&D center.fiercebiotech · 26d ago
- Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips againEbvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, joins a wave of rejected or discouraged therapies on which the FDA has re…biospace · 1mo ago
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.biopharma_dive · 1mo ago
- Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcoholA new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can quickly sober up people who have had too much to drink.fiercebiotech · 1mo ago
- North Immunology goes public via reverse merger as eczema drug heads toward clinicNorth Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.fiercebiotech · 1mo ago
- AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDWith a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…fiercebiotech · 1mo ago
- AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitisAstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…biospace · 2mo ago
- Opinion: Climate change is making people with chronic illness even sicker“What research can definitively tell us is that climate change is here, and it’s already making people sick,” writes Lorraine Boissoneault.stat · 2mo ago
comments(0)
5-min edit window · permanent after that